Publications by authors named "J Waldschmidt"

Claim this Profile
T
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan.
Anna Fleischer, Magdalena Roll, Jan H Frenking, Franziska Panther, Götz Gelbrich, Johannes Waldschmidt

Cancer Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.
Lukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, Markus Kreuz, Sofie-Katrin Kadel, Johannes Waldschmidt

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies.
Xiang Zhou, Johannes M Waldschmidt, Hermann Einsele

Blood Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice.
Heinz Ludwig, Elias K Mai, Marion Högner, Manfred Welslau, Johannes M Waldschmidt

Ann Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.
Maximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, Igor-Wolfgang Blau, Marie Harzer, Johannes Waldschmidt

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis